Pro Bono Bio was launched on 12 September 2011 in Moscow marking the visit of British Prime Minister David Cameron to encourage successful Anglo Russian technology projects and companies.
David Cameron commenting on the launch of Pro Bono Bio said “This is a great example of UK- Russia collaboration at the cutting edge of R&D. It demonstrates how British businesses can work together with their Russian counterparts to expand into new areas, creating jobs and prosperity here in the UK."
Pro Bono Bio is an international healthcare company born of such an Anglo Russian partnership, based on pharmaceutical experience in product development, commercialisation and finance in London, international capital and the investment and support of RUSNANO in Moscow.
Our vision is to create a new international pharmaceutical company based on innovation in both our product development and our business model. We partner with specialist service providers to bring the best talent to bear on key unmet medical needs. In doing so we expect to create and market several commercially important new therapies and thereby grow a new valuable healthcare company.
Pro Bono Bio launched its first medicine, FLEXISEQ, for the treatment of pain associated with osteoarthritis on 12 September 2011.
FLEXISEQ is the first of an attractive pipeline of products under development that are due for launch over the next five years. Its key benefits are:
Nearly all countries report a 10+% incidence of osteoarthritis (and chronic joint pain) and roughly half of those are diagnosed; many of which are seeking improvements in their long term treatment.
FLEXISEQ is the subject of several global patents and is a trademark beneficially owned by Pro Bono Bio.
You are welcome to explore our site to find out more. We particularly recommend you review our first product FLEXISEQ which features the new Sequessome Technology™.
Pro Bono Bio is a commercial organisation based on innovation and partnership, but it also has a core humanitarian value, with a commitment to ship free product to selected disadvantaged areas of the world matching the sales of products at normal prices elsewhere.
Pro Bono Bio is at the forefront of the "humanitarian" pharmaceutical industry. It is the first pharmaceutical company to have clear and specific humanitarian objectives from the start. Pro Bono Bio’s business model provides for the provision of drug donations to Africa based on the sales of its products in the pharmaceutical markets of Western Europe. So for every sale in Western Europe at normal prices, Pro Bono Bio will provide the same product, manufactured to the same international standards, to be distributed to Africa. Pro Bono Bio’s shareholders are fully supportive of this unique business model which will apply to all of the company’s products.
London, England 10 April 2013 –Key phase III trial data supporting Pro Bono Bio’s (“PBB”) drug-free osteoarthritis treatment FLEXISEQ...
The BVDA president, and pharmacist Thomas Hieble, explained; “The jury awarded the prize to FLEXISEQ® in recognition of the application of its innovative Sequessome Technology® to deliver symptom relief to sufferers...
The donation was made by Pro Bono Bio’s envoy Andrei Garbuz (pictured) to the head of commission for pilgrimage to holy places of Islam, Mr El Hadji Mansour DIOP in Dakar. The Commissioner General...
Pro Bono Bio is also pleased to announce that they have signed an agreement to distribute FLEXISEQ in Malaysia and the product will be available via local distribution company, Farmasia Sdn. Bhd. from early July 2012. Its first introduction to the local market is at the...